FDA committee backs Novo Nordisk ’ s once-weekly type II diabetes drug
An FDA advisory committee has voted favorably to approve Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide Type II diabetes drug.
Shares in the insulin maker were up 2% in after-hours activity today, trading at $50.13 apiece.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA committee backs Novo Nordisk’s once-weekly type II diabetes drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news